Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. has reported its Q1 2024 financial results, showcasing a net loss reduction and a promising rise in funds through warrant exercises and potential equity conversions with the EIB. The company’s CDMO unit is gaining traction with new work orders and strategic marketing, while advancing its NanoAb preclinical development for various autoimmune diseases, including a promising treatment for plaque psoriasis.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
